Hims & Hers Health, Inc.
HIMSFull coverage—Hims & Hers Health, Inc.
HIMSNew York Stock ExchangeFull coverage
Q3 fiscal 2026 edition
A free account unlocks one dossier edition a month.
Create a free accountAlready have an account? Sign in
Summary
Free to read
Hims & Hers sells prescription treatments and wellness products, mostly on subscription, to consumers who pay out of pocket through its app and website, with medicines shipped from its own pharmacies. In the third quarter of 2026 revenue grew 49% to $890.4 million, within the company's guidance, but about half of the growth came from the Eucalyptus acquisition, gross margin fell to 57% from 74% after the move from compounded to branded weight-loss drugs, and subscribers fell for the first time since at least the start of 2024. The company cut its 2026 Adjusted EBITDA guidance for the third time and reported a GAAP net loss of $33.0 million. Moatsight estimates revenue of about $3.8 billion and a GAAP net loss over the next four quarters, with the outlook resting on whether the margin of the new mix recovers and US demand returns once marketing does.
In the full dossier
- Part 1In brief
- Part 2Business explainer
- Part 3Earnings
- Part 4Valuation and projections
- Part 5What changed
General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers